Proactive Investors - Run By Investors For Investors

Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product

The deal is with the Sandoz Inc division is for the Adamis’ Symjepi product
Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product
Adamis’ Symjepi product is for the emergency treatment of allergic reactions

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares shot up almost 40% to US$4.45 on Monday after the San Diego-headquartered firm after it announced a distribution and commercialization agreement with drugs giant Novartis Group.

The deal with the latter's Sandoz Inc division is for the  Adamis’ Symjepi product for the emergency treatment of allergic reactions (Type I) including anaphylaxis.

The Symjepi injector is a competitor of Mylan's well-known EpiPen product

Sandoz will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, said Adamis.

"We are very excited about our collaboration with Sandoz," said Dr Dennis J. Carlo, the president and chief executive of Adamis.

"They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi. 

"We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.”

Adamis is a specialty biopharma company, which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.

View full NVS profile View Profile

Novartis Timeline

Newswire
April 24 2012

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
A syringe
January 30 2019
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use